High-resolution Structures of HIV-1 Reverse Transcriptase/TMC278 Complexes: Strategic Flexibility Explains Potency Against Resistance Mutations

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2008 Jan 31

PMID 18230722

Citations 146

Authors

Kalyan Das

Joseph D Bauman

Arthur D Clark Jr

Yulia V Frenkel

Paul J Lewi

Aaron J Shatkin

Stephen H Hughes

Eddy Arnold

Affiliations

Soon will be listed here.

Abstract

TMC278 is a diarylpyrimidine (DAPY) nonnucleoside reverse transcriptase inhibitor (NNRTI) that is highly effective in treating wild-type and drug-resistant HIV-1 infections in clinical trials at relatively low doses ( approximately 25-75 mg/day). We have determined the structure of wild-type HIV-1 RT complexed with TMC278 at 1.8 A resolution, using an RT crystal form engineered by systematic RT mutagenesis. This high-resolution structure reveals that the cyanovinyl group of TMC278 is positioned in a hydrophobic tunnel connecting the NNRTI-binding pocket to the nucleic acid-binding cleft. The crystal structures of TMC278 in complexes with the double mutant K103N/Y181C (2.1 A) and L100I/K103N HIV-1 RTs (2.9 A) demonstrated that TMC278 adapts to bind mutant RTs. In the K103N/Y181C RT/TMC278 structure, loss of the aromatic ring interaction caused by the Y181C mutation is counterbalanced by interactions between the cyanovinyl group of TMC278 and the aromatic side chain of Y183, which is facilitated by an approximately 1.5 A shift of the conserved Y(183)MDD motif. In the L100I/K103N RT/TMC278 structure, the binding mode of TMC278 is significantly altered so that the drug conforms to changes in the binding pocket primarily caused by the L100I mutation. The flexible binding pocket acts as a molecular "shrink wrap" that makes a shape complementary to the optimized TMC278 in wild-type and drug-resistant forms of HIV-1 RT. The crystal structures provide a better understanding of how the flexibility of an inhibitor can compensate for drug-resistance mutations.

Citing Articles

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine.

Nagarajan P, Zhou J, Di Teodoro G, Incardona F, Seguin-Devaux C, Kaiser R Viruses. 2024; 16(11).

PMID: 39599830 PMC: 11599002. DOI: 10.3390/v16111715.

Binding Selectivity Analysis from Alchemical Receptor Hopping and Swapping Free Energy Calculations.

Azimi S, Gallicchio E J Phys Chem B. 2024; 128(44):10841-10852.

PMID: 39468848 PMC: 11551962. DOI: 10.1021/acs.jpcb.4c05732.

Anti-Human Immunodeficiency Virus-1 Property of Thai Herbal Extract Kerra™.

Saehlee S, Seetaha S, Klankaew W, Srathong P, Choowongkomon K, Choengpanya K Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065767 PMC: 11279832. DOI: 10.3390/ph17070917.

Anti-Infective Activity of Extract with Molecular Docking of Its Triterpenoid Glycosides.

Aldholmi M, Ahmad R, Shaikh M, Mohammed Salem A, Alqurashi M, Alturki M Antibiotics (Basel). 2024; 13(6).

PMID: 38927210 PMC: 11200997. DOI: 10.3390/antibiotics13060544.

Inhibitors against DNA Polymerase I Family of Enzymes: Novel Targets and Opportunities.

Kannan S, Gillespie S, Picking W, Picking W, Lorson C, Singh K Biology (Basel). 2024; 13(4).

PMID: 38666816 PMC: 11048162. DOI: 10.3390/biology13040204.

References

Lewi P, De Jonge M, Daeyaert F, Koymans L, Vinkers M, Heeres J . On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. J Comput Aided Mol Des. 2003; 17(2-4):129-34. DOI: 10.1023/a:1025313705564. View

Guillemont J, Pasquier E, Palandjian P, Vernier D, Gaurrand S, Lewi P . Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem. 2005; 48(6):2072-9. DOI: 10.1021/jm040838n. View

Murshudov G, Vagin A, Dodson E . Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997; 53(Pt 3):240-55. DOI: 10.1107/S0907444996012255. View

Janssen P, Lewi P, Arnold E, Daeyaert F, De Jonge M, Heeres J . In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem. 2005; 48(6):1901-9. DOI: 10.1021/jm040840e. View

Das K, Clark Jr A, Lewi P, Heeres J, de Jonge M, Koymans L . Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1.... J Med Chem. 2004; 47(10):2550-60. DOI: 10.1021/jm030558s. View

Spence R, Kati W, Anderson K, Johnson K . Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 1995; 267(5200):988-93. PMC: 7526747. DOI: 10.1126/science.7532321. View

Himmel D, Das K, Clark Jr A, Hughes S, Benjahad A, Oumouch S . Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J Med Chem. 2005; 48(24):7582-91. DOI: 10.1021/jm0500323. View

Fang C, Bauman J, Das K, Remorino A, Arnold E, Hochstrasser R . Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A. 2007; 105(5):1472-7. PMC: 2234168. DOI: 10.1073/pnas.0709320104. View

Lindberg J, Sigurdsson S, Lowgren S, Andersson H, Sahlberg C, Noreen R . Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem. 2002; 269(6):1670-7. DOI: 10.1046/j.1432-1327.2002.02811.x. View

10.

Ren J, Nichols C, Chamberlain P, Weaver K, Short S, Chan J . Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J Med Chem. 2007; 50(10):2301-9. DOI: 10.1021/jm061117m. View

11.

Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I . High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol. 1995; 2(4):293-302. DOI: 10.1038/nsb0495-293. View

12.

Ren J, Nichols C, Chamberlain P, Weaver K, Short S, Stammers D . Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J Mol Biol. 2004; 336(3):569-78. DOI: 10.1016/j.jmb.2003.12.055. View

13.

Das K, Sarafianos S, Clark Jr A, Boyer P, Hughes S, Arnold E . Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J Mol Biol. 2006; 365(1):77-89. DOI: 10.1016/j.jmb.2006.08.097. View

14.

Rodgers D, Gamblin S, Harris B, Ray S, Culp J, Hellmig B . The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1995; 92(4):1222-6. PMC: 42671. DOI: 10.1073/pnas.92.4.1222. View

15.

Ludovici D, De Corte B, Kukla M, Ye H, Ho C, Lichtenstein M . Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett. 2001; 11(17):2235-9. DOI: 10.1016/s0960-894x(01)00412-7. View

16.

Clark Jr A, Clark P, Hughes S, Arnold E . Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors, and an antibody Fab fragment. Methods Enzymol. 1995; 262:171-85. DOI: 10.1016/0076-6879(95)62017-6. View

17.

Pauwels R . Aspects of successful drug discovery and development. Antiviral Res. 2006; 71(2-3):77-89. DOI: 10.1016/j.antiviral.2006.05.007. View

18.

Hsiou Y, Ding J, Das K, Clark Jr A, Hughes S, Arnold E . Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure. 1996; 4(7):853-60. DOI: 10.1016/s0969-2126(96)00091-3. View

19.

Das K, Lewi P, Hughes S, Arnold E . Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol. 2004; 88(2):209-31. DOI: 10.1016/j.pbiomolbio.2004.07.001. View

20.

Brunger A, Adams P, Rice L . Recent developments for the efficient crystallographic refinement of macromolecular structures. Curr Opin Struct Biol. 1998; 8(5):606-11. DOI: 10.1016/s0959-440x(98)80152-8. View